Gw Pharmaceuticals ShareCast News (GWP)

GW Pharmaceuticals announces US patent allowance for pain relieving treatment

AIM-listed biopharmaceutical company GW Pharmaceuticals has reported that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for US application serial number 13/606,742, a patent application directed to the spray device of its Sativex product formulation.
[22 Apr '13]

GW Pharmaceuticals unveils German pricing decision on Sativex

AIM-listed specialty pharmaceutical company GW Pharmaceuticals expects to account for a provision of 0.8m pounds in the financial year ending September 30th 2013 reflecting the impact of a pricing decision on its multiple sclerosis treatment Sativex.
[19 Mar '13]

GW Pharmaceuticals gets more clinical backing

GW Pharmaceuticals, the British biotech firm, has seen clinical data released by partner Almirall that gives further backing for the efficacy of GW's cannabis-based drug, Sativex.
[12 Oct '12]

Small caps round-up: Acta, GW Pharma, Pure Wafer

Clean energy products company Acta has announced the shipment of the first fully integrated fuel cell telecom back-up power system, incorporating Acta's onboard hydrogen generation for automatic fuel replenishment. The completed system has been shipped to Acta's Australian marketing and distribution partner and is to be put on field trial with a major Australian telecoms company in the near future. The company said that on the basis of a five-year total cost of ownership, the
[1 Oct '12]

GW Pharma MS drug gets German approval

GW Pharmaceuticals has been given a lift after German authorities gave the thumbs up to its multiple sclerosis drug Sativex.
[22 Jun '12]

Journal of Pain review boost for GW Pharm

GW Pharmaceuticals, the developer of cannabis-based medicinal products, has released a puff piece about a favourable review of its Sativex product in a US medical journal.
[23 Apr '12]

Ophir Energy director makes massive sale

A round-up of the biggest director deals today so far.
[2 Apr '12]

Tuesday tips round-up: Elementis, Genus, GW Pharmaceuticals

Elementis traces its roots to 1844 and the Harrisons & Crosfield tea and coffee trading conglomerate, but it took its present shape in 1998, when the company focused on chemicals found in substances such as paint, cosmetics and, more recently, shale gas wells, where the flow of a substance needs to be controlled. Elementis, which trades on 15 times Brewin Dolphin forecasts, has shed its volatile past and consistently overdelivered on the earnings front. It looks to be in its element and could flow higher, says the Times.
[5 Jul '11]